Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Self-medication is not advisable
Liraglutide (Saxenda) Saxenda received FDA approval on December 23, 2014 as the first GLP 1 receptor agonist specifically indicated for chronic weight management
33 EdwardsonC
Adverse effects LC is generally well-tolerated
Taken together, the figure highlights a key mechanistic principle underlying the therapeutic rationale for multi-agonist strategies: while GLP-1R monotherapy achieves meaningful metabolic and hepatic benefits exclusively through indirect, systemic pathways, the addition of GIPR and - most importantly - GCGR co-agonism introduces complementary and increasingly direct hepatic mechanisms, providing the pharmacological basis for the superior efficacy observed with dual and triple agonists in MASLD/MASH
9 GLP-1RAs should not be prescribed in patients with a history of pancreatitis, a personal or family history of medullary thyroid cancer, or multiple endocrine neoplasia due to the observed development of thyroid tumors in animal studies
US$ 22.97
US$ 29.29
US$ 27.90
US$ 27.00
US$ 24.52
